Online citations, reference lists, and bibliographies.

Consensus Guidelines For The Management And Treatment Of Neuroendocrine Tumors.

P. Kunz, D. Reidy-Lagunes, L. Anthony, E. Bertino, Kari Brendtro, J. Chan, H. Chen, R. Jensen, M. Kim, D. Klimstra, M. Kulke, E. Liu, D. Metz, A. Phan, R. Sippel, J. Strosberg, J. Yao
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.
This paper references
10.1097/MPA.0b013e3181ebb4f0
The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer
H. Chen (2010)
10.1200/JCO.2007.15.2553
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
D. Kwekkeboom (2008)
10.1016/S1072-7515(00)00222-2
Hepatic neuroendocrine metastases: does intervention alter outcomes?
R. Chamberlain (2000)
10.1097/MPA.0b013e3181ec124e
The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems
D. Klimstra (2010)
10.1097/MPA.0b013e3181ebb168
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
M. Kulke (2010)
10.1097/MPA.0b013e3181ec1261
The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum
L. Anthony (2010)
10.1097/01.sla.0000161981.58631.ab
Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?
J. Touzios (2005)
10.1016/S0140-6736(11)61742-X
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
M. Pavel (2011)
10.1097/01.sla.0000232556.24258.68
Aggressive Surgery Improves Long-term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience
P. Schurr (2007)
10.1097/01.RVI.0000232177.57950.71
Update on the management of neuroendocrine hepatic metastases.
D. Madoff (2006)
10.1097/MPA.0b013e3181ebb2a5
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum
J. Boudreaux (2010)
10.1056/NEJMoa1003825
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
E. Raymond (2011)
10.1200/JCO.2009.22.8510
Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group.
R. Arnold (2009)
10.1097/MPA.0b013e3181ec1380
NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus)
A. Phan (2010)
10.1002/cncr.25425
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
J. Strosberg (2011)
10.1016/J.YPED.2011.06.042
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
J. A. Stockman (2012)
10.1097/PAS.0b013e3181ce1447
Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set
D. Klimstra (2010)
10.1016/S1072-7515(03)00230-8
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
J. Sarmiento (2003)
10.1038/ncponc1326
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors
D. Reidy (2009)
10.1097/MPA.0b013e3181ebb56f
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
J. Strosberg (2010)
10.1210/jc.2011-0666
Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
J. Yao (2011)



This paper is referenced by
10.1111/bcp.12698
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
Fredrik Tiberg (2015)
Modern Surgical Treatment and Genomic Profiling of Pancreatic Neuroendocrine Neoplasms - from the Operating Theater to the Gene Lab
Sven-Petter Haugvik (2016)
Gastrointestinal neuroendocrine tumors: slow but steady progress.
Arvind Dasari (2014)
10.1016/j.critrevonc.2015.08.005
Gastrointestinal cancers in inflammatory bowel disease: An update with emphasis on imaging findings.
M. Barral (2016)
10.21037/tgh.2016.11.03
Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms.
Huangying Tan (2016)
Prospective Evaluation of Results of Reoperation ison Syndrome in Zollinger-Ell
Jeffrey A. Norton (2018)
10.1007/s12029-018-0160-x
Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database
Maxine D. Fisher (2018)
10.14341/SERG9572
Radionuclide imaging and therapy in patients with neuroendocrine tumors
Olga D. Baranova (2018)
10.1016/j.hpb.2018.09.020
Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.
J. Mansour (2019)
10.1016/j.critrevonc.2019.102835
Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
Hirotaka Ishida (2019)
10.1002/cam4.1598
Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population‐based study
Q. Zhong (2018)
10.1007/978-3-319-16205-8_6
Incidentalomas of the Pancreas
John C Mcauliffe (2016)
10.3390/jcm8091455
Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care
B. Woodhouse (2019)
10.1007/s11864-019-0690-x
Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors
Haley Hauser (2019)
10.1007/978-3-319-96681-6_12
Tumors of the Gastrointestinal System Including the Pancreas
M. Taggart (2020)
10.3748/wjg.v21.i32.9512
Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.
J. Cloyd (2015)
10.1016/j.jpedsurg.2016.01.004
Risk-reduction surgery in pediatric surgical oncology: A perspective.
J. Sandoval (2016)
10.1159/000439434
Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor
F. Grillo (2015)
10.5114/aoms.2017.65449
Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up
Ş. Yalçın (2017)
10.3390/ijms18010143
Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future
A. Ohmoto (2017)
10.1007/978-3-662-56533-9_9
Neuroendokrine Tumoren des Pankreas
Kim Christin Honselmann (2018)
10.1016/j.ijscr.2014.11.045
Pancreatic neuroendocrine tumor with splenic vein tumor thrombus: A case report
Rodrigo Rodríguez Rodríguez (2014)
10.5114/pjp.2016.65864
[Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas].
Łukasz Liszka (2016)
10.1080/10408363.2018.1525335
Novel biomarkers of cardiovascular disease: Applications in clinical practice
M. Lyngbakken (2019)
10.1186/s40792-020-0792-5
Metachronous liver metastases after long-term follow-up of endoscopic resection for rectal neuroendocrine neoplasms: a report of three cases
Yuma Hane (2020)
10.1136/bcr-2018-225014
Primary small cell neuroendocrine carcinoma of the anterior mediastinum presenting with trepopnea
Mohamed Iliyas (2018)
10.1159/000463386
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro
E. T. Aristizabal Prada (2017)
10.1097/MPA.0000000000000846
The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society
J. Howe (2017)
10.1097/MD.0000000000009009
Gastroenteropancreatic—origin neuroendocrine carcinomas
Yong Gyun Won (2017)
10.2217/IJE-2016-0018
Recent advances in the management of endocrine malignancies associated with hereditary hyperparathyroidism syndromes
Yulong Li (2017)
10.1016/j.clinre.2019.08.010
Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients.
Regis Souche (2019)
10.1016/j.suc.2016.07.002
Surgical Management of Pancreatic Neuroendocrine Tumors.
Jason B Liu (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar